Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.Merck & Co Inc's MRK Keytruda (pembrolizumab) is indicated for numerous cancer types.Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate ...